A survey shows the physical and psychological distress associated with anemia due to chronic kidney disease, with 41% of patients reporting that they feel socially isolated

ADDLESTONE, England, May 23 / PRNewswire / – – More than half of the patients surveyed said that their illness determines their everyday lives

– Experts demand more understanding and better support

– Astellas Pharma Europe Ltd. today published the results of a European survey of 200 nephrologists and 203 patients with chronic kidney disease anemia. The study reveals the stress on the physical and mental health of patients caused by the disease. Over half of the patients surveyed reported that their illness determines their everyday life (57%), with 41% of the patients expressing feelings of social isolation due to their condition. Experts believe that a deeper understanding of the patient burden of chronic kidney failure anemia is needed among healthcare professionals, along with a greater focus on patient quality of life in daily routine.

Anemia is a common complication of chronic kidney disease, affecting one in five people.1 It leads to symptoms such as lack of energy, fatigue, and shortness of breath2 that can affect patients both at work and at home. The results of the survey show that the symptoms influenced the everyday life of 83% of the surveyed patients, which led to absenteeism of more than eight days per month on average. For almost half of the patients surveyed (44%), their condition meant that they had to stop working for an indefinite period of time. In addition to the work, more than two-thirds of the patients surveyed (67%) reported that they needed help around the house, which further illustrates the far-reaching effects of the anemia caused by kidney failure on the quality of life of the patients. The survey infographic provides additional insight from patients and nephrologists about the diagnosis, management, and the stress of living with anemia due to kidney disease.

Astellas appointed a team of five external experts to provide their views on the survey results. The team of experts included two senior nephrology professors (United Kingdom and Spain), a specialist renal nurse (United Kingdom), the president of a European association of renal nurses and the president of a national patient group (Spain). A detailed overview of the survey results and the assessments of the expert team can be found in the comprehensive survey report. The following key observations and actions were identified by the team of experts for future condition management:

“There is a clear need for a better understanding of what aspects of a patient’s condition affect their quality of life.” Jennifer Ann Williams, Specialized Kidney Nurse, Abertawe Bro Morgannwg University Health Board, UK.

“It’s no surprise that patients experience social isolation because of their condition. They’re tired and don’t want to go out or meet friends. They just don’t want to do anything.” Kidney Diseases (ALCER), Spain.

“It is important to consider the individual characteristics of the patient when it comes to the effects of anemia on everyday life.” Professor José Portolés Pérez, nephrologist at the University Hospital Puerta de Hierro de Majadahonda, Spain.

Together, these findings from patients, nephrologists and experts show that nephrologists need a better understanding of the psychological and physical stress on patients caused by anemia in renal insufficiency and that the patient’s quality of life needs to be given greater consideration in the treatment of the disease.

“At Astellas, tomorrow’s change is the ethos that guides everything we do. We recognize that addressing unmet needs is often best achieved in collaboration with others. This survey is just one of the initiatives we are engaged in with patient groups and professional organizations work to provide value to people with chronic kidney disease, their loved ones and the healthcare professionals who treat their condition. ” Gino Ciotti, Medical Director for Medical Affairs, Nephrology, Astellas.

To learn more about chronic kidney disease anemia, visit us at: www.astellas.com/eu/therapy-areas/nephrology

About Beyond CKD: The Hidden Truth Behind Anemia

Between January and February 2020, research firm Research Partnership conducted a survey on behalf of Astellas Europe Limited to investigate the assessment of patients and nephrologists regarding chronic kidney disease and the anemia it causes.

The participants were recruited through online committees and were suitable if:

– a patient has been diagnosed with anemia due to renal insufficiency.
– a nephrologist who has been practicing for at least two years and who has treated at least eight patients with anemia due to renal insufficiency from the third stage. The participants took part in a 25-minute quantitative online survey.

You can find out more about the survey at www.astellas.com/eu/media-centre/media-resources.

About chronic kidney disease and anemia

Renal insufficiency is characterized by a progressive loss of kidney function, which is caused by damage to the kidneys as a result of symptoms such as high blood pressure, diabetes or immune-regulated inflammatory conditions.3 One in ten people worldwide lives with chronic kidney disease.4 In Europe, one in eight people lives with it chronic kidney disease.4 According to data from the United Kingdom, every fifth patient with chronic kidney disease has anemia. In people with the most severe kidney disease (stage 5 kidney failure), this rate increases to every second patient.1 Globally, it is forecast that chronic kidney disease will be the fifth leading cause of premature death by 2040.5 It is a critical health problem worldwide, the one brings great and growing unmet medical needs with it.

Anemia is a common complication of chronic kidney failure, 6 resulting from the failure of the kidneys to produce erythropoietin, decreased oxygen uptake, and increased hepzidine and iron deficiency due to chronic inflammation. This is related to significant morbidity and mortality in both dialysis and non-dialysis patients, increasing in both incidence and severity as kidney disease progresses.7 Anemia in kidney disease increases the risk of adverse effects on the cardiovascular system, deteriorating kidney outcome and can have a negative impact on patients’ quality of life.8-10

About Astellas

Astellas Pharma Inc. is a pharmaceutical company operating in over 70 countries worldwide. We support the focus-area approach, which aims to identify opportunities for the continuous development of new drugs to treat diseases with high unmet unmet medical needs by focusing on biology and modality. We also look beyond our fundamental Rx focus to create Rx + ® solutions for the healthcare sector that combine our specialist knowledge and experience with cutting-edge technology in the various fields of activity of external partners. With these accomplishments, Astellas is at the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/eu.

Astellas warnings

This press release contains statements relating to current plans, estimates, strategies, and beliefs and other statements that are not historical facts but forward-looking statements about Astellas’ future performance. These statements are based on the current assessments and beliefs of management in view of the information currently available to it. They involve known and unknown risks and uncertainties. Various factors could cause actual results to differ materially from the forward-looking statements. These factors include, but are not limited to: (i) changes in the general economic situation and laws and regulations pertaining to the pharmaceutical markets, (ii) currency fluctuations, (iii) delayed launches of new products, (iv) poor marketing by Astellas of existing and new products, (v) Astellas ‘inability to continue effective research and development of products that are accepted by customers in highly competitive markets, and (vi) third party infringement of Astellas’ intellectual property rights.

Any drug information (including products currently under development) featured in this press release is not intended to be used as advertising or as medical advice.


1 Dmitrieva O, de Lusignan S, Macdougall IC, et al. Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data. BMC Nephrol 2013;14:24.

2 National Kidney Foundation. Anemia and Chronic Kidney Disease. Erhältlich unter: https://www.kidney.org/atoz/content/what_anemia_ckd. [Letzter Aufruf: Juni 2020]

3 Ojo A. Addressing the Global Burden of Chronic Kidney Disease Through Clinical and Translational Research. Trans Am Clin Climatol Assoc 2014;125:229-246.

4 International Society of Nephrology. Chronic Kidney Disease. Global Kidney Health Atlas 2017. Erhältlich unter: www.theisn.org/global-atlas (http://www.theisn.org/global-atlas) [Letzter Aufruf: Juni 2020].

5 Institute for Health Metrics and Evaluation (IHME). Findings from the Global Burden of Disease Study 2017. Seattle, WA: IHME, 2018. Erhältlich unter: http://www.healthdata.org/sites/default/files/files/policy_report/2019/GBD_2017_Booklet.pdf [Letzter Aufruf:: Juni 2020].

6 McClellan W, Aronoff SL, Kline Bolton W, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004;20:1501-1510.

7 Stauffer ME und Fan T. Prevalence of Anemia in Chronic Kidney Disease in the United States. PLoS One 2014;9:e84943.

8 Mohanram A, Zhang Z, Shahinfar S, et al. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004;66:1131-1138.

9 Weiner DE, Tighiouart H, Stark PC, et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 2004;44:198-206.

10 Eriksson D, Goldsmith D, Teitsson S, et al. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrol 2016;17:97.

Press contact:

Product communication
Kate Burd
Tel.: +44 7771 803076
Email: kate.burd@astellas.com

Original content by: Astellas Pharma Europe Limited, transmitted by news aktuell
Original message: https://www.presseportal.de/pm/61801/4717685


Tour de France 2020 | Lenard Kämna won the next stage, Roglič is still leading

He took a chance, brought the escape to a victorious end. German Lenard Kämna won the sixteenth stage of the Tour de France. He managed the last tens of kilometers very well, at the end of the introductory alpine act of the 107th year of the famous cycling race he also passed the climber Ricardo Carapaz from Ecuador. Swiss Sebastian Reichenbach finished third. Slovenian Primož Roglič also made a big loss in the group of biggest favorites. However, he safely defended the yellow jersey 40 seconds in front of his compatriot Tadej Pogačar and will ride in it tomorrow for the eighth day in a row.


After the second free Monday, the race entered the final third week today. The 16th stage from La Tour-du-Pin to Villard-de-Lans, 164 km long, was waiting for the peloton. It was the first of three challenging alpine series in a row.

And according to experts, ideal for a large escape. The assumptions were met. Strong stables and favorites for the overall championship were left by a large group, from which Kämna was the first to reach the finish line in Villard-de-Lans. At the age of 24, he won his first victory on the Tour. It was the premiere triumph this year for the Bora-hansgrohe stable

Profile 16. etapy Tour de France.

The main peloton did not arrive until almost seventeen minutes late. The captain of the Jumbo-Visma Roglič team lightly watched the yellow jersey in the lee, and the others also saved their strength for Wednesday’s most difficult climb of the whole year. It will finish on the Col de la Loze at an altitude of 2304 meters after a 20-kilometer descent.

With a loss of more than 27 minutes, the group arrived with Jan Hirt or the defending champion of the Colombian Egan Bernal, just behind them Roman Kreuziger came as one of the last.

All 156 remaining cyclists can continue to Paris, where the destination will traditionally be on Sunday. The organizers announced that all 785 tests on covid-19 performed on riders and escorts during Sunday and Monday were negative. No competitor has been positive since the start of the Tour on August 29th.

Tour de France – 16th stage: La Tour-du-Pin – Villard-de-Lans (164 km):
1. Kämna (Germany / Bora-hansgrohe) 4:12:52
2. Carapaz (Ekv./Ineos Grenadiers) -1: 27
3. Reichenbach (Switzerland / Groupama-FDJ) -1: 56
4. Sivakov (Rus./Ineos Grenadiers) -2:34
5. Geschke (DEU / CCC) -2: 35
6. Barguil (Fr./Arkea-Samsic) -2:37
7. Benoot (Belg./Sunweb) -2: 41
8. Roche (Ir./Sunweb) -2:47
9. Pacher (Fr./B&B Hotels-Vital Concept) -2:51
10. Alaphilippe (Fr./Deceuninck-Quick Step) -2:54
137. Hirt (CR / CCC) -27: 27
147. Kreuziger (CZE / NTT) -27: 49
Running order:
1. Roglič (Slovin./Jumbo-Visma) 70:06:47
2. Pogačar (Slovenian / SAE Team Emirates) -40
3. Uranium (Col./EF Pro Cycling) -1: 34
4. López (Kol./Astana) -1:45
5. A. Yates (Brit./Mitchelton-Scott) -2:03
6. Gate (Austr./Trek-Segafredo) -2: 13
7. Landa (Sp. / Bahrain-McLaren) -2: 16
8. Mas (Šp. / Movistar) -3: 15
9. Dumoulin (Niz./Jumbo-Visma) -5: 19
10. Quintana (Kol./Arkea-Samsic) -5:43
80. Hirt -2:53:10
105. Kreuziger -3:32:29


Saakashvili declared the need for an anti-elite revolution in Ukraine :: Politics :: RBC

Ukraine may become the “industrial hub of Europe”, but this requires “other taxes, the need for courts,” and “the bureaucracy needs much less,” Saakashvili said

Photo: Stringer / RIA Novosti

All attempts at reform in Ukraine led to nothing, and those who feel good at the “feeding trough” remained on the ground, said former President of Georgia and ex-governor of the Odessa region Mikhail Saakashvili on the program “Freedom of Speech of Savik Shuster”. On the eve of May 7, President of Ukraine Vladimir Zelensky appointed Saakashvili as head of the executive committee for reform of Ukraine.

“An anti-bureaucratic, anti-elite revolution is about to happen in Ukraine. All those people who feel so good at this “feeding trough”, they have not gone anywhere, they have remained. And they wait until this fervor passes away from us, people who want changes will weaken, and they will say again that we said that they didn’t succeed, we warned you, ”said Saakashvili (quoted from the Internet publication “Censor.net”).

According to him, there is “only a few months” to avoid this. “It’s better to listen to us, old experienced professionals,” Saakashvili said.

He also said that “enterprises are leaving China” and Ukraine may again become the “industrial hub of Europe.” However, in order to attract investors, “completely different taxes are needed, courts are needed”, and “bureaucracy needs much less.” In particular, the Ukrainian anti-corruption court, in Saakashvili’s opinion, is still “small and very clumsy,” and the National Anti-Corruption Bureau, although “also does not take bribes,” can work “much better.”

Zelensky called the recall of the Georgian ambassador to Ukraine because of Saakashvili a mistake

Vladimir Zelensky